PTAFR and chronic obstructive pulmonary disease: In this study, we found that PAFR antagonist rupatadine, which is a clinical used PAFR and H1 receptor dual inhibitor, suppresses CSE induced autophagic cell death, decreases the release of elastase from neutrophils, protects mice from CS caused COPD.